Acute Effects of Intravenous Administration of Pamidronate in Patients with Osteoporosis by Lim, Mie Jin et al.
© 2010 The Korean Academy of Medical Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pISSN 1011-8934
eISSN 1598-6357
Acute Effects of Intravenous Administration of Pamidronate  
in Patients with Osteoporosis
We investigated acute effects of intermittent large dose bisphophonate therapy in 
osteoporotic patients. Peripheral blood mononuclear cells were incubated with alendronate 
(100 μM) for 18 hr, in vitro and cytokine expressions were measured by real-time RT-PCR. 
Pamidronate 30 mg was administered on 26 osteoporotic patients; and acute phase 
reactants, inflammatory cytokines and bone biomarkers were measured. The in vitro study 
showed significant increase in mRNA expression of IL-6, TNF-α and IFN-γ. A notable rise in 
serum C-reactive protein (CRP) was observed over 3 days after pamidronate infusion 
(P=0.026). Serum levels of TNF-α, IL-6 and IFN-γ were also significantly increased (P=0.009, 
0.014, 0.035, respectively) and the increase in IL-6 levels were strongly correlated with CRP 
levels (P=0.04). Serum calcium and c-telopeptide levels rapidly decreased after the 
treatment (P=0.02, <0.001, respectively). This study showed that mRNA expression of 
inflammatory cytokines at peripheral blood mononuclear cells (PBMC) level were observed 
within 18 hr and marked elevation of inflammatory cytokines and acute phase reactants 
were demonstrated after pamidronate infusion at the dose for osteoporosis. Our studies 
confirmed that intermittent large dose aminobisphosphonate causes acute inflammation.
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INTRODUCTION
Bisphosphonate is the treatment of choice for osteoporosis, 
Paget’s disease, hypercalcemia of malignancy and some other 
skeletal complications of malignancy. Bisphosphonates are syn-
thetic analogues of inorganic pyrophosphate (PPi) and consist 
of two phosphonate groups linked by nonhydrolysable phos-
phoether bonds to a central carbon atom, which is also attached 
to two covalently bonded side chains (R1 and R2). This backbone 
structure enables bisphosphonates to bind strongly to divalent 
metal ions such as Ca
2+ at osteoclastic resorption sites and inhibit 
osteoclast function (1). Bisphosphonates are classified into two 
groups based on their modes of action. First generation bisphos-
phonates, which do not contain nitrogen, form non-hydrolyz-
able ATP analogues (2) and disrupt osteoclast function by being 
incorporated into toxic non-hydrolyzable adenosine triphos-
phate analogs. On the other hand, new generation bisphospho-
nates, which have a nitrogen containing side chain, inhibit the 
farnesyl diphosphonate synthase, a component of the choles-
terol mevalonate pathway, and thereby disrupt cell signaling 
and cause apoptosis (3). 
  Despite their comparative efficacies, second generation bis-
phosphonates have well established toxicities, such as, fever 
accompanied by mild flu-like symptoms like fatigue, myalgia 
and arthralgia (4). These side effects are specific to new genera-
tion bisphosphonates and typically occur in about one-third of 
patients administered aminobisphosphonate for the first time 
(4). Furthermore, clinical features of pyrexia with transient de-
creases in leukocyte and lymphocyte counts and increases in CRP 
levels are highly suggestive of an acute phase response (4-6). 
  Recent progress has elucidated the mechanism underlying 
acute phase response induced by aminobisphosphonate. Pub-
lished data suggested that the stimulations of proinflammatory 
cytokines, such as, IL-6 and tumor necrosis factor α (TNF-α), 
played a key role in pathogenesis of bisphosphonate induced 
fever (6-8). And Santini et al. (9) suggested that interferon γ 
(IFN-γ) was involved in the pathogenesis of acute phase re-
sponse and in the antiangiogenic action of bisphosphonate in 
cancer patients. 
  Both alendronate and pamidronate are the aminobisphos-
phonates. Alendronate is either given daily or weekly for a month 
while pamidronate is usually administered every 3 months in-
travenously.
  Several studies have been conducted on acute phase response 
to aminobisphosphonate but they were done at doses for malig-
nancy (6-8). No study was performed regarding how the ami-
nobisphosphonate affected patients at the dose usually used to 
treat osteoporosis. Therefore, the aim of the present study was Lim MJ, et al.  •  Acute Effects After Bisphosphonate Administration
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to investigate the acute-phase response in patients with rheu-
matism after administration of aminobisphosphonate at the 
dose for osteoporosis. 
MATERIALS AND METHODS
In vitro study: Blood sampling and isolation of peripheral 
blood mononuclear cells (PBMCs)
Twelve osteoporotic patients were included and the diagnosis 
of osteoporosis was met the ISCD guideline (10). After obtain-
ing an informed consent, venous blood (15 mL) samples were 
drawn in the heparin containing syringe. 
  After centrifugation, the blood cells were diluted 1:1 with RPMI 
1640 (Hyclone, Logan, UT, USA) wash media containing 2% fetal 
calf serum, layered over the Histopaque (HISTOPAQUE-1077, 
Sigma, St. Louis, MO, USA) and centrifuged at 693 g for 30 min 
at 25˚C. In each case, PBMC layer at inter-phase between plas-
ma and Histopaque was collected and washed twice in RPMI 
1640. Cell pellets obtained by centrifugation were resuspended 
in RPMI1640/FCS. The number of PBMC in the suspensions 
was counted using a hemocytometer.
RNA extraction and reverse transcription
Cell pellets of 1×10
6 cells were used for each RNA expression. Cell 
pellets were lysed by 1 mL of Trizol reagent (Invitrogen, Carls-
bad, CA, USA) to prepare total RNA. The cDNA was synthesized 
using a reverse transcription system (AMV reverse transcriptase, 
Promega, Madison, WI, USA). 
Culture of mononuclear cells
PBMC (5×10
5) were cultured in the 96 well plate in RPMI 1640, 
supplemented with 2 mM glutamine and 100 IU/mL of benzyl 
penicillin, streptomycin (100 μg/mL) (Invitrogen, Carlsbad, CA, 
USA), 10% heat-inactivated fetal bovine serum (FBS) (Hyclone), 
and human M-CSF, Macrophage colony-stimulating factor, 
(Sigma) in a CO2 incubator at 37˚C. Every 4-5 days 50% of the 
media were changed.
Incubation (pulse) of the PBMCs with alendronate
PBMC were incubated with or without alendronate (100 μM) 
for about 18 hr in separate culture tube and washed. PBMC were 
either cultured further or RNA was extracted from the cells to 
determine the short-term effect of bisphosphonate. 1×10
6 cells 
were harvested for RNA extraction. 
mRNA expressions of the inflammatory cytokines in the 
PBMC 
The sequences of the RT-PCR primers and the real time RT-PCR 
probes used are shown in Table 1. The real-time RT-PCR was 
performed using an iCycler iQ Real-Time PCR Detection System 
(Bio-RAD, Hercules, CA, USA). The amplification reactions were 
performed in 25 μL final volume containing 12.5 μL of iQ Super-
mix (Bio-RAD), 1 μL of primer, 2 μL of TaqMan probe, 1 μL of 
cDNA, and 7.5 μL of distilled water. Thermal cycling conditions 
were; 10 min at 95˚C followed by 50 amplification cycles of 30 
sec at 95˚C and 1 min at 60˚C. Real time RT-PCR CT value were 
calculated using computer software (iCycler, Bio-Rad). Results 
were analyzed by 2
-∆∆CT relative gene expression quantification 
method using GAPDH as an internal standard (11). Samples were 
processed in duplicate. 
Patients for in vivo study
Twenty-six osteoporotic patients were included in the study. 
Inclusion/exclusion criteria were as follows. Patients were os-
teoporotic (BMD <T score -2.5), but without history of bisphos-
phonate administration. In addition, patients were required to 
have at study entry, neutrophil count ≥1.5×10
9/L, electrolytes 
within the normal range, normal hepatic and renal function, 
and no acute or chronic infections as reflected by a normal se-
rum C-reactive protein (CRP) level (<0.3 mg/dL). Patients were 
considered ineligible if they had received chemotherapy or im-
munosuppressant during the previous 6 months, or had taken 
steroid dose equivalent to more than 10mg of prednisolone with-
in previous 1 week. This study was conducted after obtaining 
Inha university institutional review board approval (No. 2006-201) 
and informed consent was obtained from all patients.
Table 1. The sequences of the quantitative real time PCR primers and probes
Target Primer name Sequence (5´-3´)
GAPDH GAPDH F
GAPDH R
GAPDH TM
GAPDH hexTM
gAAggTgAAggTCggAgTC
gAAgATggTgATgggATTTC
6FAM-CAAgCTTCCCgTTCTCAgCCT-BHQ 1
HEX-CAAgCTTCCCgTTCTCAgCCT-BHQ 1
RANK TNFRSF11 F
TNFRSF11 R
TNFRSF11 TM
CTggACCAACTgTACCTTCCTTg
AAgCCTCATTgATCCAgTgCC
FAM-ATCCgATgCggTTTgCAgTTCTTC-BHQ1
RANKL TNFSF11 F
TNFSF11 R 
TNFSF11 TM
AAAgCgATggTggATggCT 
CCCAACCCCgATCATggTA 
HEX-CTTTATgggAACCAgATgggATgTCggT-BHQ1
TNF-α TNF F
TNF R
TNF TM
CCTgTAgCCCATgTTgTAgCAAA
ATggTgTgggTgAggAgCAC 
HEX-TgggAgTAgATgAggTACAggCCCTC-BHQ1
IL-1 IL1B F
IL1B R 
IL1B TM
ggCCCTAAACAgATgAAgTgCTC
CCAgCATCTTCCTCAgCTTgTC
FAM-CTgAAgCCCTTgCTgTAgTggTggT-BHQ1
IL-6 hu IL-6 F
hu IL-6 R
IL-06 TM
CCAgAgCTgTgCAgATgAgTACA
CCTgCAgCTTCgTCAgCA 
FAM-CATTTgTggTTgggTCAggggTggT-BHQ1
IFN-γ IFNg-F 
IFNg-R 
IFNg-TM  
CAgAgCATCCAAAAgAgTgTg S         
ggACATTCAAgTCAgTTACCgA A      
AggAAgACATgAATgTCAAgTTTTTCAATAgCA-BHQ1
TRAP ACP5-F 
ACP5-R
ACP5-TM
gCCACgATCACAATCTgCAgTA 
TgAgTCTTCAgTCCCATAgTggAAg
FAM-ATgAgAATggCgTgggCTACgTgCT-BHQ1
Cathepsin K CTSK-F
CTSK-R
CTSK-TM
CTTCCAgTTTTACAgCAAAggTg
TTgTTTCCCTTCTggATTCCA 
FAM-TgAAAgCTgCAATAgCgATAATCTgAACCAT-
BHQ1Lim MJ, et al.  •  Acute Effects After Bisphosphonate Administration
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In vivo study design 
This was an open, prospective study about the acute effects of 
pamidronate (intravenous, 30 mg in 500 mL of 0.9% saline over 
3 hr) including the acute phase inflammatory response. The acute 
phase reactants, erythrocyte sedimentation rate (ESR) and CRP 
were measured just before the treatment and 24, 48 and 72 hr 
afterwards. Venous blood were examined for inflammatory cy-
tokine levels (TNF-α, IL-6 and IFN γ), white blood cell (WBC) 
count, absolute neutrophil count (ANC), monocyte count and 
for bone tunrover markers including serum calcium, serum c-
telopeptide (CTX). The blood for osteoclast culture was drawn 
into EDTA tubes before and after 48 hr after pamidronate infu-
sion. For serum cytokine determinations, blood was rapidly cen-
trifuged and the serum was kept at -70˚C before analysis. 
Analysis of parameters
Serum levels of IL-6, TNF-α, IFN-γ and CTX were measured with 
enzymeimmunometric assay kits (serum IL-6 and TNF-α, R&D 
Systems, Minneapolis, MiN., USA; serum IFN-γ, eBioscience, 
San Diego, CA, USA; serum CTX, Nordic Bioscience Diagnos-
tics, Bolden, UK). The mean minimum detectable concentra-
tions of IL-6, TNF-α, IFN-γ and CTX were 0.039 pg/mL, 0.106 
pg/mL, 4 pg/mL and 0.020 ng/mL, respectively. Samples were 
analyzed in duplicate. ESR was measured with the Westergren 
method, and serum CRP was determined by latex agglutination 
using a Hitachi 747 (Hitachi, Tokyo, Japan). 
Cytochemical assessment of osteoclast formation
Venous blood samples were diluted 1:1 in a-MEM, layered over 
Histopaque-1077 and centrifuged at 711 g for 30 min. The PBMC 
layers were collected and washed in a-MEM. PBMC (1×10
6 cells/ 
well) were placed in a 96-well tissue culture plate and cultured 
for 14 days in a-MEM containing 10% serum, 100 units/mL pen-
icillin, 100 μg/mL streptomycin, 50 ng/mL of M-CSF (Macrophage 
colony-stimulating factor) and 100 ng/mL of receptor activator 
for nuclear factor κ B ligand (RANKL). The cells were incubated 
at 37˚C in a CO2 incubator. After 14 days of culture histochemi-
cal staining for tartrate resistant acid phosphatase (TRAP) was 
carried out using an acid phosphatase kit (Sigma 386-A) accord-
ing to the manufacturer’s instruction. TRAP positive giant cells 
with more than 3 nuclei were regarded as osteoclasts. The num-
bers of the osteoclasts were expressed as the counts per well. 
Statistical analysis
Data are expressed as mean±SD (Standard Deviation). The 
mRNA expressions of the cytokines which were measured by 
real time RT-PCR were analyzed by Wilcoxon’s test for nonpara-
metric dependent variables.
  Serum cytokine levels and the number of osteoclasts in sam-
ples cultured before treatment (basal value) were also compared 
with those detected in PBMCs at 48 hr after drug infusion using 
Wilcoxon’s test for nonparametric dependent variables. Deter-
minations of acute phase reactant levels such as ESR and CRP 
before and at day 1, 2 and 3 days after treatment were carried 
out using repeated measure ANOVA. Spearman rank correla-
tion coefficients were used to examine the correlation between 
cytokine levels and CRP. Significance was accepted for P values 
of <0.05.
RESULTS
The demographic characteristics of patients enrolled both in vi-
tro and in vivo studies are described in Table 2.
In vitro expression of inflammatory cytokines after 
alendronate incubation 
After incubating PBMCs with alendronate for 18 hr, the mRNA 
expressions of inflammatory cytokines increased; IL-6 mRNA 
expression increased most prominently among them. In addi-
tion, IFN-γ also showed a significant increase. The TNF-α mRNA 
expression was also elevated, but the IL-1 mRNA expression 
did not change significantly compared to pre-incubation level 
(Table 3).
Expression of bone metabolism-related markers after 
incubation with alendronate 
The mRNA expression of cathepsin K increased after incubation 
with alendronate, but other osteoclastogenic cytokines showed 
Table 2. Demographic characteristics of patients
Parameters
in vitro Study
(blood donors)
in vivo Study
(drug infusion)
Total number 12 26
Median age (range, yr) 63 (49-80) 55 (29-88)
Male/Female 2/10 4/22
Median BMD, bone mineral density 
   (L-spine, T-score)
 -2.95 -2.3
Median BMD, bone mineral density 
   (femur neck, T-score)
-2.6  -2.54
No. of patients using steroid   6   9
No. of patients using statins   2   2
Table 3. In vitro mRNA expression* of inflammatory cytokine and bone turnover markers 
after incubation with alendronate
Molecules Post-incubation P
TNF-α 2.88±2.34 0.003
IL-1 1.52±0.95 0.126
IL-6 30.24±68.89 0.003
IFN-γ 19.39±19.99 0.003
RANK 0.73±0.71 0.117
RANKL 2.06±2.53 0.556
TRAP 1.03±0.51 0.695
Cathepsin K 2.44±2.81 0.041
*The mRNA express ion of inflammatory cytokines and bone turnover markers were 
calculated using 2
-∆∆CT method. The numbers of post incubation are ratio to pre-incu-
bation level and pre-incubation level is regarded as 1.Lim MJ, et al.  •  Acute Effects After Bisphosphonate Administration
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no significant change. The mRNA expression of RANKL and TRAP 
increased marginally and the mRNA expression of receptor ac-
tivator for nuclear factor κB (RANK) showed a slight change 
compare to that of baseline (Table 3).
Acute phase reactants after in vivo pamidronate infusion 
A continuous increase in serum CRP levels was observed dur-
ing three consecutive days after treatment (Fig. 1). Mean basal 
CRP was 0.13±0.10 mg/dL and this rose to 0.26±0.30 mg/dL on 
day 1, to 0.55±0.73 mg/dL on day 2 and to 1.33±2.70 mg/dL on 
day 3, and these increases were significant (P=0.026). However, 
increases observed in ESR levels were not significant (P=0.312). 
Inflammatory cytokine synthesis after in vivo pamidronate 
infusion
All serum inflammatory cytokine levels were significantly ele-
vated at 48 hr after pamidronate infusion (Fig. 2). Specifically, 
TNF-α increased from 1.89±2.51 pg/mL at baseline to 2.33±2.78 
pg/mL (P=0.009); and IL-6 increased from 1.98±1.72 pg/mL at 
baseline to 3.94±4.62 pg/mL (P=0.014). Increase of IL-6 levels 
were found to be correlated with those of CRP (P=0.040). IFN-γ 
increased from 20.56±32.99 μg/mL at baseline to 21.40±13.29 
μg/mL at 48 hr after administration and the increase was also 
significant (P=0.035). 
Changes in bone turnover markers after pamidronate 
infusion
The serum levels of bone turnover markers showed a rapid de-
cline after pamidronate infusion (Table 4). Serum CTX which 
was 0.47±0.33 ng/mL at baseline, decreased to 0.14±0.10 ng/mL 
on day 2 (P<0.001), and serum calcium, which was 9.31±0.32 
mg/dL at baseline, dropped to 8.98±0.47 mg/dL at 48 hr after 
Table 4. Changes in the serum level of bone turnover markers after pamidronate 
infusion
Markers Baseline Post-pamidronate P
Serum CTX (ng/mL) 0.47±0.33 0.14±0.10 0.000
Serum calcium (mg/dL) 9.31±0.32 8.98±0.47 0.020
Fig. 1. The acute effect of pamidronate on CRP (A) and ESR (B). CRP increased significantly for three consecutive days (P=0.026) whereas ESR increased only marginally (P= 
0.312). Statistical analysis was carried out using repeated measure ANOVA.
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the drug administration (P=0.020).
Effect of pamidronate on hematologic parameters
Hematologic parameters, namely WBC, ANC and lymphocyte 
counts decreased slightly. Monocyte counts were unchanged 
by pamidronate infusion (Table 5). 
Effect on osteoclastogenesis 
TRAP positive cells with more than three nuclei were regarded 
as osteoclasts. The number of TRAP positive giant cells formed 
after culturing PBMCs were 47.1±43.9 cells/well at baseline, and 
this decreased to 37.6±51.1 cells/well on day 2 but this reduc-
tion was not statistically significant (P=0.080).
DISCUSSION
Our preliminary in vitro study on the effect of alendronate (100 
μM) on PBMCs after incubation for 18 hr showed that the mRNA 
expressions of the inflammatory cytokines such as IL-6, TNF-α 
and IFN-γ increased. This finding indicates that mRNA expres-
sions of the inflammatory cytokines occur as early as 18 hr after 
the administration at the cell level while the symptoms of acute 
phase response occur 24-36 hr after administration (4).
  The subsequent in vivo study was undertaken to determine 
whether pamidronate infusion affects the productions of these 
inflammatory cytokines after administrating a usual dose of 
pamidronate at 30 mg. It was found that pamidronate significant-
ly increased both serums IL-6 and TNF-α levels in vivo, which 
concurs with the findings of previous studies (7, 8).
  As acute phase reactant, CRP levels were found to increase 
steadily over three consecutive days following pamidronate in-
fusion. IL-6 has been known to play a key role in the stimulation 
of synthesis of CRP by the hepatocytes (12) and it was interest-
ing to find in the present study that increment in IL-6 and CRP 
significantly correlated each other.
  The mechanism for acute phase response and the identities 
of the effector cells that release IL-6, TNF-α and IFN-γ have been 
recently reported (13). During the inhibition of the mevalonate 
pathway by aminobisphosphonate, the metabolic intermediates, 
such as, isopentenyl pyrophosphate (IPP) accumulated. IPP 
was a potent activator of human peripheral blood γδ T cells (14). 
When activated, the γδ T cells rapidly produced large quantities 
of IL-6, TNF-α and IFN-γ (13, 15). During a ‘typical’ acute phase 
response, monocytes and macrophages were major source of 
the cytokines but during acute phase response to bisphospho-
nate, human γδ T cells produced these proinflammatory cyto-
kines (13), activated by bisphosphonate as the antigen present-
ed on the surface of monocyte lineage cells (15). The potencies 
of aminobisphosphonates appeared to correlate inflammatory 
milieu. The aminobisphosphonates with stronger potencies in-
crease more IPP production, which led to the activation of larg-
er numbers of peripheral blood γδ T cells and as such, more 
proinflammatory cytokines were induced (16). 
  The intermittent large dose bisphosphonate for cancer treat-
ment increased bioavailability and also the incidence of acute 
phase response (17). This seemed to be the reason why many 
studies on acute phase response were carried out at the dose for 
treatment of cancer (7, 8, 18-20). In these studies, transient py-
rexia was found to be associated with increases in inflammato-
ry cytokines, whereas in our patients elevated temperatures 
were rarely observed (data not shown). One Korean study report-
ed that acute phase response occurred in 55.6% of osteoporotic 
patients after administration of intravenous pamidronate but the 
symptoms were mostly mild such as myalgia and febrile sense 
persisting for less than 2 days (21). Therefore we tried to figure 
out whether bisphosphonate affected inflammatory cytokines 
in osteoporotic patients. And it was confirmed in this study that 
inflammatory cytokines and acute phase reactants were signifi-
cantly increased regardless of elevation of body temperature. 
The dose of pamidronate required to treat osteoporosis was suf-
ficient to cause an acute phase response within 48 hr after the 
administration although it barely affected hematopoietic param-
eters. Sauty et al. (7) found significant decreases in lymphocyte 
and leukocyte counts after a 60 mg pamidronate infusion 48 hr 
afterwards, which was twice the dose used in our study.
  Nevertheless, even at the dose which caused barely no change 
on hematologic parameters, pamidronate was found to affect 
bone metabolism within 48 hr after administration. The declines 
in serum CTX and serum calcium at 48 hr after administration 
suggested that the intermittent large dose pamidronate have a 
rapid onset of action. 
  One interesting observation in the present study was that 
mRNA expression of IFN-γ was increased in in vitro and in vivo 
studies. A previous study on pamidronate 60 mg also showed 
elevated serum IFN-γ level in in vitro study (22) and another 
study confirmed this at 90 mg dose of pamidronate in vivo (9). 
IFN-γ is a pleiotropic cytokine that is secreted by activated CD4 
and CD8 T cells and has immunomodulatory effect. Some evi-
dences indicated it had an antiangiogenic effect by inhibiting 
endothelial proliferation (23). One of the worst side effects of 
bisphosphonate, osteonecrosis of the jaw (ONJ) was known to 
be associated with its antiangiogenic effect (24). Despite the in-
cidents of ONJ at the dose used to treat malignancies, bisphos-
phonate was regarded safe for the treatment of osteoporosis (25). 
However, as intermittent large dose bisphosphonate therapy is 
Table 5. Hematologic parameters after pamidronate infusion
(/μL) Baseline Post-administration P
WBC     6,753±1,805    6,388±2,076 0.213
ANC    3,837±1,859    3,748±1,597 0.925
Monocyte counts    427±152    427±128 0.757
Lymphocyte counts 2,122±875 1,799±808 0.083Lim MJ, et al.  •  Acute Effects After Bisphosphonate Administration
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favored nowadays, the probability of ONJ would be increasing; 
increase in IFN-γ in our in vitro and in vivo studies supported 
this hypothesis.
  The limitation of this study is that different bisphosphonate 
was used in vitro and in vivo studies. Both alendronate and pami-
dronate are aminobisphosphate and have very similar proper-
ty. Intravenous regimen of alendronate has not been available 
to date and this study was performed before the introduction of 
intravenous ibandronate. In order to test on the hypothesis of 
this study, we chose the only aminobisphosphate, pamidronate, 
which was allowed in human use for intravenous injection. We 
assumed that both of them would cause similar inflammatory 
reactions.
  In conclusion, acute phase response is noted after intrave-
nous administration of aminobisphosphonate at osteoporotic 
dose. Our studies confirmed that intermittent large dose ami-
nobisphosphonate therapy causes acute inflammation despite 
rapid efficacy on osteoporosis; hence we suggest that intermit-
tent large dose bisphosphonate should be used with caution.
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